NCT05220410CompletedPhase 2
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
Source: ClinicalTrials.gov · Last updated 24 Dec 2025
Brief summary (registry, in English)
This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 21 Jan 2022
- Start date
- 28 Mar 2022
- Primary completion date
- 12 May 2025
- Lead sponsor
- Sheppard Pratt Health System
- Diseases
- Depression
- NCT number
- NCT05220410
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 20
- From 28 Mar 2022 to the primary completion date, 12 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current or past history of schizophrenia, psychotic disorder, bipolar disorder, borderline personality disorder, etc.
- Current alcohol or substance use disorder
Who the study is looking for
- Between 18 and 65 years of age at Screening
- Diagnosis of Major Depressive Disorder (MDD)
- Significant level of suicidal thoughts with active ideation and without immediate intent
- Failure to respond to 2 medications in the current episode
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheppard Pratt Health System Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
Related publications
- Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial.J Clin Psychiatry · 2026 · PMID 42138588
This page is information, not medical advice. Discuss any trial with your doctor.